drugset / Trial / NCT05703542
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is: * BXCL701
Timeline
- Start
- 2023-02-02
- Primary completion
- 2026-03-17
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BXCL701 | Peptide | — | Oral |